循环肿瘤细胞在乳腺癌新辅助化疗中的应用进展

·综 述·

Progress in the application of circulating tumor cells in neoadjuvant chemotherapy for breast cancer

Pathologic complete response （pCR） is an indicator of survival benefit in patients with neoadjuvant chemotherapy for breast cancer, and serves as a surrogate endpoint for accelerating the approval of neoadjuvant chemotherapy. However, there are currently common methods for evaluating the efficacy of neoadjuvant chemotherapy, such as clinical palpation and imaging （mammography, mammography, mammography, etc.）, so it is necessary to look for new biological indicators to predict neoadjuvant chemotherapy for breast cancer. Efficacy and prognosis can be used as a reference for the next step of accurate treatment. Circulating tumor cells （CTC） is a tumor cell that detaches from the primary tumor tissue into the blood circulation and is a new type of “liquid biopsy” tumor biomarker. At present, CTC can replace tissue samples by non?invasive methods for pathological diagnosis, disease monitoring, molecular sequencing, etc., which can be used for dynamic monitoring and prognosis. Using CTC to establish a personalized cancer treatment program is an important and reliable way to achieve accurate treatment of breast cancer. This article reviews the progress in the application of circulating tumor cells in neoadjuvant chemotherapy for breast cancer.